Results 91 to 100 of about 33,833,464 (200)

Magnetic Nanomedicine for Cancer: Mechanisms, Modalities, and Translation

Nano Select, Volume 7, Issue 9, September 2026.
At the convergence of nanotechnology, precision oncology and intelligent therapeutics, magnetic nanoparticles (MNPs) are redefining how cancer is detected, targeted and treated. This review critically examines the mechanisms enabling their integration in imaging, targeted drug delivery and magnetic hyperthermia, while exploring how intelligent design ...
Shivani Kadam, Rahul M. Sonavale, Ratnesh Das, Jayant Pawar, Nutan Shukla, Zhengyou Li, Girish R. Pathade, Nishabh Kushwaha, Asha Patel, Sushilkumar A. Jadhav, Samuel B. Adeloju   +10 more
wiley   +1 more source

Milia en plaque – therapeutic response to calcipotriol

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Veronika Hall, Johannes M. Weiss
wiley   +1 more source

Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development

Cancer Science, Volume 117, Issue 9, Page 2335-2344, September 2026.
Dysregulated cell cycle control often involves alternative compensatory pathways in cancers to maintain its robustness but provide unique targetable vulnerabilities. We overview recent insights on cancer‐specific vulnerabilities across the cell cycle and discuss how these can be used to develop new therapeutic strategies.
Nana Kamakura, Minji Jo, Motoko Takahashi, Toru Hirota   +3 more
wiley   +1 more source

KIF14 and citron kinase act together to promote efficient cytokinesis [PDF]

, 2006
Multiple mitotic kinesins and microtubule-associated proteins (MAPs) act in concert to direct cytokinesis (Glotzer, M. 2005. Science. 307:1735-1739). In anaphase cells, many of these proteins associate with an antiparallel array of microtubules termed ...
Erich A. Nigg, Chan, E. H. Y., Francis A. Barr, Eunice H.Y. Chan, Neef, Rüdiger, Nigg, EA, Xiuling Li, Rüdiger Neef, Gruneberg, Ulrike, Nigg, E. A., Gruneberg, U, Chan, EH, Chalamalasetty, R. B., Nigg, Erich A., Chalamalasetty, Ravindra B., Neef, R, Grüneberg, U., Chalamalasetty, RB, Barr, Francis A., Barr, FA, Li, Xiuling, Ravindra B. Chalamalasetty, Neef, R., Barr, F. A., Chan, Eunice H. Y., Ulrike Gruneberg, Li, X, Li, X. L.   +27 more
core   +1 more source

Polo-like kinase-1 controls Aurora A destruction by activating APC/C-Cdh1.

PLoS ONE, 2009
Polo-like kinase-1 (Plk1) is activated before mitosis by Aurora A and its cofactor Bora. In mitosis, Bora is degraded in a manner dependent on Plk1 kinase activity and the E3 ubiquitin ligase SCF-betaTrCP. Here, we show that Plk1 is also required for the
Renske van Leuken, Linda Clijsters, Wouter van Zon, Dan Lim, XueBiao Yao, Rob M F Wolthuis, Michael B Yaffe, René H Medema, Marcel A T M van Vugt   +8 more
doaj   +1 more source

Polo-like Kinase 4 Shapes Up [PDF]

, 2014
Polo-like kinase 4 (Plk4) is a master regulator of centriole duplication and targets to centrioles through the association of its cryptic polo box domain with centriole receptors.
Holland, Andrew J., Levine, Michelle S.
core   +1 more source

Oncogenic potential of BEX4 is conferred by Polo-like kinase 1-mediated phosphorylation

Experimental and Molecular Medicine, 2018
Cancer: an enabler for defective division Tumors exploit a signaling mechanism that allows them to survive disruptions in cell division that would normally prove lethal.
Jin-Kwan Lee, Geun-Hyoung Ha, Hyun-Soo Kim, Chang-Woo Lee   +3 more
doaj   +1 more source

Polo-like Kinase 1 as a Target for Anti-tumor Therapy

Klinicka onkologie, 2015
Individual proteins from polo-like kinase (Plk) family fulfil different but critical functions in regulating cell cycle and coordinate cell response to DNA  damage. The most studied one from this five  member family is Plk1. It is a serine/ threonine kinase that plays a pivotal role in many aspects of mitosis and its deregulation is common in various ...
I, Procházková, B, Vojtěšek
openaire   +2 more sources

Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.

PLoS ONE, 2014
BackgroundPolo-like kinase-1 (Plk1) plays a crucial role in cell proliferation and the inhibition of Plk1 has been considered as a potential target for specific inhibitory drugs in anti-cancer therapy.
Ganipisetti Srinivasrao, Jung-Eun Park, Sungmin Kim, Mija Ahn, Chaejoon Cheong, Ky-Youb Nam, Pethaiah Gunasekaran, Eunha Hwang, Nam-Hyung Kim, Song Yub Shin, Kyung S Lee, Eunkyung Ryu, Jeong Kyu Bang   +12 more
doaj   +1 more source

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate

Acta Pharmaceutica Sinica B, 2019
Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment. Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity.
Sara Abdelfatah, Angela Berg, Qi Huang, Li Jun Yang, Sami Hamdoun, Anette Klinger, Henry J. Greten, Edmond Fleischer, Thorsten Berg, Vincent K.W. Wong, Thomas Efferth   +10 more
doaj   +1 more source